Day 1 - Sunday, 3 December 2017
Meeting category
Date(s)
3 Dec 2017 - 7 Dec 2017
Location
Hawaii,
United States
HEP DART 2017
Related Enduring Materials
Enduring Materials
-
Eliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs
Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study
Novel Nucleosides, CMCP and CFCP, Potently Block the Infectivity and Replication of Wild-type and Drug-resistant HBVs in Culture and in Human-liver-chimeric Mice and Show Potential QW or Q2W (not available)
Dr. H. Mitsuya
NIH, USA
Day 2 - Monday, 4 December 2017
-
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
A Tale of Two Viruses: HBV and HCV Co-infection (not available)
Jake Liang
NIH, USA
The Global Burden of Non-alcoholic Steatohepatitis (not available)
Zobair Younossi
Inova Health System, USA
Hepatitis B/C and NASH: Crossroads Between Science and Business (not available)
Geoffrey Meacham
Barclays Biotech/Pharma Research, USA
Elucidating the structural and dynamic mechanism of resistance for clinically relevant variants against HCV NS3/4A protease inhibitors (not available)
Dr. A. Matthew
University of Massachusetts, USA
Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study (not yet available)
Catch me if you can – tuning immunity for HBV cure (not available)
Ulrike Protzer, MD
Technical University of Munich, Germany
Immunology of HBV
Optimizing Infection Systems and Screens and Studying Innate anti-HBV Factors and Mechanisms.
Personalized Approaches to HBV Cure
Is Host Genome Integrated HBV Relevant? - The Con Perspective
Victorian Infectious Diseases Reference Laboratory
Is Host Genome Integrated HBV Relevant? - The Pro Perspective
Day 3 - Tuesday, 5 December 2017
-
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Endpoints and New Targets for Curing Hepatitis B
Victorian Infectious Diseases Reference Laboratory
Targeting the HBV-Macrophage-Stellate cell axis to treat HBV-induced Liver Diseases
In vivo evaluation of anti-HBV CRISPR/Cas9 therapy in the FRG mouse
A novel immunotherapy for chronic HBV and HDV infections that bypass tolerance and induce broadly crossreactive and neutralizing antibodies (not available)
Dr. M. Sallberg
Karolinska Institutet, Sweden
Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination
Emerging Therapeutic Targets and Concepts for Delta Hepatitis Virus (not yet available)
Is there a best Direct Acting Antiviral in development?
Is There a Best Host Acting Antiviral for HBV Cure?
Is there a best immunomodulator in development?
New directions towards functional cure of Chronic Hepatitis B
SB 9200: A novel RIG-I agonist for chronic hepatitis B
Victorian Infectious Diseases Reference Laboratory
Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure
Immunotherapy is coming for HCC
Studies of the HBV-immune modulator AIC649 (not yet available)
Day 4 - Wednesday, 6 December 11 2017
-
Clinical Challenges in HCV infection
Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia (not available)
Joseph Doyle, MD
Monash University, Australia
When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR? (not available)
Paul Pockros
Scripps Translational Science Institute, USA
DAA Controversies: Do they Cause HBV Reactivation and/or HCC?
Long term follow-up after treatment with Ombitasvir/Paritaprevir/ritonavir ±Dasabuvir ±Ribavirin in the AMBER – real world experience study
A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization
Predicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors
Evolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside (not available)
Michael Fried
University of North Carolina, USA
Sustained SVR 2 years after HCV treatment with simeprevir, daclatasvir and sofosbuvir in patients with portal hypertension or decompensated liver disease (not available)
Dr. E. Lawitz
Texas Liver Institute, USA
High Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study
Update on Prophylactic HCV Vaccine Development
Lessons learned towards a Vaccine and Functional Cure for HIV (not available)
Mario Stevenson
University of Miami, USA
Hepatitis B virus splice variants are associated with and predictive of Liver cancer
Seroclearance of HBsAg in Chronic Hepatitis B Virus Patients on Lamivudine, Tenofovir or Entecavir Therapy: A 10 Year Experience.
Day 5 - Thursday, 7 December 2017
-
The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations
Liver Directed Acetyl-CoA Carboxylase Inhibitor GS-0976 For NASH (not available)
Adrian Ray
Gilead Sciences, USA
RNA Interference Screen Identified Farnesoid X Receptor (FXR) as a Host Dependency Factor for HBV Establishment in Primary Human Hepatocytes
Evidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)
Two Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years
An Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells (not yet available)
Establishment of functional control and normalization of liver function in HBeAg negative chronic HBV infection following combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon α-2a.
Validation of a novel Transient Elastography for the measurement of liver fibrosis
Overview
Thank you to all Faculty members and delegates who participated in this year's HEP DART, which was held from 3 - 7 December 2017.
We look back at a very successful meeting with key speakers, exciting lectures, and great oral abstract presentations. We hope you enjoyed the event as much as we did, in beautiful Kona, Hawaii!
We would like to thank our sponsors once more, as this meeting would not have been possible without them:
Abbvie, Arbutus Biopharma, Emory University, Gilead, Janssen, the Raymond F. Schinazi & Family Foundation, W.H. Prusoff Foundation, Chiatai Tianqing Pharmaceutical Group, The Blatt Family Foundation, Galmed Pharmaceuticals, and The Hepatitis B Foundation.
An additional thank you to our contributors: Arrowhead Pharmaceuticals, Contrivir Pharmaceuticals Inc. and ST. Pharm Co., plus our meeting partners Erasmus Medical Center, and the International Symposium on HIV and Emerging Infectious Diseases. Your support has been invaluable.
Again, we thank you for your contribution and attendance.
The Program Chairs,
Raymond Schinazi, PhD, DSC, and Charles Boucher, MD, PhD
Committees
The Committees of HEP DART consist of experts with a tremendous amount of experience and knowledge in the field of hepatology. This meeting, therefore, promises to offer a high-quality program. Please find below the Committees behind HEP DART 2017.
Organizing Committee
Scientific Committee
|
Geoffrey Dusheiko |
University College London, UK |
|
Harvey Alter |
NIH, USA |
|
Ralf Bartenschlager |
University of Heidelberg, Germany |
|
Adrian Di Bisceglie |
Saint Louis University, USA |
|
Michael Fried |
University of North Carolina, USA |
|
Robert Gish |
Robert G. Gish Consultants, LLC, USA |
|
Brent Korba |
Georgetown University, USA |
|
Shyamasundaran Kottilil |
Maryland University, USA |
|
George Lau |
Hong Kong, China |
|
Stanley Lemon |
University of North Carolina, |
|
Stephen Locarnini |
Victorian Infectious Diseases |
|
Anna Lok |
University of Michigan Medical Center, USA |
|
Michael Manns |
Hannover Medical School, Germany |
|
Patrick Marcellin |
Hopital Beaujon, France |
|
John McHutchison |
Gilead Sciences, Inc., USA |
|
Marion Peters |
University of California, San Francisco, USA |
|
Jason Grebely |
University of New South Wales, Australia |
Support
Platinum Level
Gold Level
RFS & Family Foundation
W.H. Prusoff Foundation
Sliver Level
Bronze Level
Meeting Partners
